Publication at Faculty of Medicine in Hradec Králové |
2019
Abstract
Monoclonal antibodies are one of the main pillar in the treatment of nonHodgkin lymphoma patients. The most often used anti CD20 antibody is rituximab.
It is standard of care in most of the nonHodgkin, CD20 positive lymphoma. Obinutuzumab seems to be more effective in the first line treatment of follicular lymphoma patients and is used in combination with bendamustine in rituximab refractory cohort of patients.
Subcutaneous rituximab is now wide used in routine clinical practice. Biosimilar rituximab is given to many patients with nonHodgkin lymphoma as less expensive and effective option.
All segment of monoclonal antibody therapy is crucial for improvement of results of therapy in nonHodgkin lymphoma patients.